Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma.

Cancer research·2026

Same author

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.

Science translational medicine·2026

Same author

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.

Neuro-oncology·2024

Same author

Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation.

Nature metabolism·2024

Same author

Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.

The Journal of experimental medicine·2024

Same author

CAR-T cell manufacturing: Major process parameters and next-generation strategies.

The Journal of experimental medicine·2024

Same journal

HuR degrader knocks down BRAF in cancer.

Nature reviews. Drug discovery·2026

Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026

Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026

Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026

Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026

Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 6, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Navigating CAR-T cells through the solid-tumour microenvironment.

Andrew J Hou¹, Laurence C Chen¹, Yvonne Y Chen^2,3,4

¹Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA, USA.

Nature Reviews. Drug Discovery

|May 11, 2021

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy shows promise for solid tumors by overcoming challenges like immunosuppressive microenvironments and targeting specific antigens. Engineering strategies aim to enhance T-cell specificity and function for improved cancer treatment.

More Related Videos

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

Related Experiment Videos

Last Updated: Nov 6, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptor (CAR) T-cell therapy is highly effective against B cell malignancies.
Solid tumors present unique challenges, including limited tumor-exclusive antigen targets and immunosuppressive microenvironments.
These challenges restrict the safety and efficacy of current CAR T-cell therapies for solid tumors.

Purpose of the Study:

To review protein- and cell-engineering strategies for next-generation CAR T-cells.
To enhance CAR T-cell specificity and effector function against solid tumors.
To overcome obstacles limiting CAR T-cell efficacy in solid malignancies.

Main Methods:

Review of protein-engineering strategies.
Review of cell-engineering strategies.
Analysis of approaches to enhance tumor specificity and effector function.

Main Results:

Identified key challenges in solid tumor microenvironments.
Highlighted strategies to improve CAR T-cell targeting and persistence.
Discussed methods for overcoming immunosuppression and metabolic hurdles.

Conclusions:

Next-generation CAR T-cells require advanced engineering to effectively treat solid tumors.
Protein and cell engineering are crucial for enhancing tumor specificity and sustained function.
Overcoming the solid tumor microenvironment is essential for therapeutic success.